Newton Charles W. 4
4 · Keros Therapeutics, Inc. · Filed Mar 11, 2026
Research Summary
AI-generated summary of this filing
Keros Therapeutics (KROS) Director Charles W. Newton Receives Awards
What Happened
Charles W. Newton, a director of Keros Therapeutics (KROS), received two equity grants on March 9, 2026: 13,215 restricted stock units (RSUs) and a derivative award covering 14,788 shares. Both were reported with an acquisition price of $0.00 (i.e., awards/compensation, not an open‑market purchase or sale). The combined grant covers 28,003 shares that will convert to stock or become exercisable only as they vest.
Key Details
- Transaction date: March 9, 2026 (reported on Form 4 filed March 11, 2026). Filing appears timely under the two‑business‑day rule.
- Grants: 13,215 RSUs (code A) and 14,788 derivative shares (code A) — $0.00 reported price (award/compensation).
- Vesting: RSUs vest over three years in 12 equal quarterly installments, first vesting May 15, 2026 (F1). The derivative/option shares vest over three years in equal quarterly installments, first vesting June 9, 2026 (F2). Vesting is subject to continuous service.
- Shares owned after transaction: not specified in the provided filing details.
- No indication of immediate sale or exercise; these are compensation grants, not market purchases or sales.
Context
These grants are routine director compensation and do not represent an open‑market purchase (which some investors view as a stronger near‑term bullish signal). RSUs convert to actual shares only as they vest; derivative/option grants similarly require vesting (and possibly exercise) before becoming tradeable stock.
Insider Transaction Report
- Award
Common Stock
[F1]2026-03-09+13,215→ 13,215 total - Award
Stock Option (Right to Buy)
[F2]2026-03-09+14,788→ 14,788 totalExercise: $11.35Exp: 2036-03-08→ Common Stock (14,788 underlying)
Footnotes (2)
- [F1]Represents a restricted stock unit ("RSU") award. The RSUs shall vest over a three-year period in twelve equal quarterly installments with the first such vesting to occur on May 15, 2026, subject to the Reporting Person's continuous service through each such vesting date.
- [F2]The shares subject to the option shall vest over a three-year period in equal quarterly installments with the first such vesting to occur on June 9, 2026, subject to the Reporting Person's continuous service through each such vesting date.